ELMIRON (pentosan polysulfate sodium) and the Risk of Pigmentary Maculopathy
Issued December 15, 2020
Issue
Cases of pigmentary maculopathy have been reported with long-term use of ELMIRON. These changes may be irreversible, and retinal and vision changes may progress even after cessation of therapy.
Hazard description
Product safety
Get notified of similar recallsEnter your email to receive alerts when new recalls are issued by the same agency.
Subscribed. You'll get an email when new recalls are issued.
RecallTracker